Effect of oridonin-mediated hallmark changes on inflammatory pathways in human pancreatic cancer (BxPC-3) cells

Figure 3 Oridonin reduces both the expression of signal transducer and activator of transcription 3 in BxPC-3 cells and the release of interleukin-6 into the supernatant. A: Enzyme-linked immunosorbent assay analysis of the effect of oridonin treatment on interleukin (IL)-6 in BxPC-3 cells. Data are expressed as mean ± SD. ^bP < 0.01 vs the control treatment; B: Western blot analysis of the effect of oridonin treatment on the levels of signal transducer and activator of transcription 3 (STAT3) and phospho-STAT3 in BxPC-3 cells treated with 0, 8, 16, or 32 μg/mL oridonin for 24 h. Three independent experiments were performed, and a representative result is shown.